AGS Geriatric Evaluation and Management Tools (Geriatrics E&M Tools) support clinicians
and systems that are caring for older adults with common geriatric conditions. n Minor depression: 15% of older peoplen Major depression: 6%–10% of older adults in primary care clinics; 12%–20% of nursing home residents; n Bipolar disorder: Common among aged psychiatric patients; does not “burn out” in old agen Suicide: n Older age associated with increasing risk of suicide n One fourth of all suicides occur in people > 65 years n Risk factors: depression, physical illness, living alone, white male, alcoholism n Violent suicides (eg, firearms, hanging) are more common than nonviolent methods among older adults, despite the potential for drug overdosing n Not useful for assessing treatment response n 9-item Patient Health Questionnaire (PHQ-9) n 9 items cover diagnostic criteria for major depression n Initial 2 questions can be used for screening n Serial administrations may assess response to treatment n Not reliable in patients with moderate to severe dementia If not currently treated, rescreen in 2 weeks. If currently treated, optimize antidepressant Start antidepressant therapy; obtain psychiatric consultation if suicidality or psychosis n Side effects of drugs for other illnesses may be confused with depressive symptoms n Medical illness can mimic depression: thyroid disease, conditions that promote apathy, fatigue,
diminished appetite, disturbed sleep
n Dementia has overlapping symptoms: impaired concentration, loss of interest, apathy, psychomotor
retardation; sleep disturbance
n Bereavement: most disturbing symptoms resolve in 2 months; no marked functional impairment
n Bipolar disorder:
n Elevated, irritable, or expansive mood persisting for at least 1 week, plus 3 of the following: inflated self-esteem, grandiosity; hypersexuality; marked increase in activity; markedly decreased need for sleep; pressured speech; racing thoughts, flight of ideas; distractibility n Grandiose or paranoid delusions may be present n Older patients are more likely to have an admixture of depression that presents as irritability n Refer to a psychiatrist due to frequency of recurrence, psychosis, and suicidality
n Psychotic depression:
n Patients have sustained paranoid, guilty, or somatic delusions n Among older patients, most commonly seen in those needing inpatient psychiatric care n In primary care, may be seen when patients exhibit unwarranted suspicions, somatic symptoms, or n Inquire about DSM-IV diagnostic criteria for major depression n Five or more of the following symptoms have been present during the same 2-week period and represent a change from previous functioning and at least one of the symptoms is either
depressed mood or anhedonia: depressed mood; anhedonia; insomnia or hypersomnia; appetite
changes or unintentional weight changes; psychomotor agitation or retardation; loss of energy; feelings of worthlessness or guilt; difficulty concentrating or making decisions; recurrent thoughts of suicide or n Diagnosis in older patients is difficult because they often report somatic symptoms and less often report depressed mood; they may present with “masked” depression with preoccupation with physical n Acute phase: Patient begins taking antidepressants to achieve remission of depressive symptoms
n Continuation phase: Once remission of symptoms is achieved, patient remains on antidepressants at
therapeutic doses for an additional 6 months to maintain symptom-free state (prevent relapse) n Maintenance phase: Patient remains on antidepressants at therapeutic doses to prevent future
recurrence of depression. The duration of maintenance therapy should be based on the frequency and severity of previous depressive episodes and may need to be lifelong. Maintenance treatment (>3 years) is provided to patients with bipolar disorders or a history of depression complicated by psychosis, suicidality, First-line therapy: Selective serotonergic reuptake inhibitors (SSRIs)
n Side effects: anxiety, agitation, nausea and diarrhea, sexual effects, pseudo-parkinsonism, increases warfarin effect, other drug interactions, hyponatremia/syndrome of inappropriate antidiuretic hormone secretion; falls and fractures in nursing home residents Second-line therapy: bupropion (150–300 mg/day)
n Increases activity of dopamine/norepinephrinen Generally safe, well toleratedn Side effects: insomnia, anxiety, tremor, myoclonus; associated with 0.4% risk of seizures Second-line therapy: venlafaxine (75–300 mg/day)
n Acts as SSRI at low doses; at higher doses, as SNRI n Effective for major depression and generalized anxietyn Side effects: nausea, hypertension, sexual dysfunction Second-line therapy: duloxetine (20–60 mg/day)
n Equally SSRI and SNRIn Effective for major depression and FDA-approved for neuropathic painn Precautions: drug interactions, chronic liver disease, alcoholism, serum transaminase elevation Second-line therapy: mirtazapine (15–45 mg at night)
n Norepinephrine, 5-HT2, and 5-HT3 antagonistn May be used for patients with depression and dementia, nighttime agitation, weight lossn Side effects: weight gain, increased appetiten Soluble tablet that dissolves in the mouth (not sublingual) Monoamine oxidase inhibitors
n Use if patient is resistant to other antidepressantsn Side effects: orthostatic hypotension, fallsn Life-threatening hypertensive crisis if taken with tyramine-rich foods, cold remedies n Fatal serotonin syndrome possible if taken with SSRI, meperidine Tricyclic antidepressants
n Nortriptyline and desipramine most appropriate for older patientsn For severe depression with melancholic features; avoid if patient has conduction disturbance, heart disease, intolerance to anticholinergic side effects n Only 50% of patients with major depressive disorder fully respond to initial treatment n Another 1/3 recover with antidepressant switch, addition of a second antidepressant, or psychotherapyn Of those who recover, 40%–60% experience recurrence, depending on severity of first episode and n Most common prescribing error is not reaching the recommended dose in first 2 weeksn For nonresponse or intolerance, switch to another SSRI or another drug classn For partial response to an SSRI, add bupropion or buspirone n Effective for treatment of major depression and mania CONVULSIVE n First-line treatment if patient is at serious risk of suicide, or for life-threatening refusal of food, fluids, THERAPY (ECT) medications
n Standard for psychotic depression in older adults; response rate 80%
n Anterograde amnesia improves rapidly after treatment
n Retrograde amnesia is more persistent; may lose total recall of events prior to treatment
n Lasting effects not shown in longitudinal studies
n Right unilateral treatment: fewer side effects but less effective than bilateral
n Contraindications:
n Recent myocardial infarction or stroke and unstable coronary artery disease increase risk of complicationsn Continue pharmacotherapy following completion of ECT treatmentn May use maintenance ECT to prevent relapse Sources: Pacala JT, Sullivan GM, eds. Geriatrics Review Syllabus: A Core Curriculum in Geriatric Medicine. 7th ed. New York, NY: American Geriatrics Society; 2010; and GRS Teaching Slides Web site Copyright 2012 by the American Geriatrics Society.


Microsoft word - manualmain.doc

VLS-AIM INTERFACE MODULE MANUAL INTRODUCTION The information is this manual is intended as an installation guide for the Videx intercom to SmartDisc/SmartTel digital video transmission system. This manual should be read carefully before the installation commences. Any damage caused to the equipment due to faulty installations where the information in this manual h

Dermapharm GmbH, A-1090 Wien Volon A 40 mg-Kristallsuspension-Ampulle GZ 123.662 Z.Nr. 14.008 Volon A 40 mg-Kristallsuspension-Spritzampulle GZ 126.027 Z.Nr. 16.439 Fachinformation, Seite 1 von 12, Stand August 2006 Fachinformation (Zusammenfassung der Merkmale des Arzneimittels) Bezeichnung des Arzneimittels Volon® A 40 mg-Kristallsuspension-Ampulle Volon® A

Copyright © 2010 Find Medical Article